Former Novo Nordisk vice chair to step down

Maj Invest CEO and regular board member at Novo Nordisk, Jeppe Christiansen, is not seeking re-election at the pharmaceutical firm’s AGM.

Jeppe Christiansen, CEO at Maj Invest | Photo: Pr / Novo Nordisk

by christian bundgaard, translated by daniel pedersen

On Thursday, March 23, Novo Nordisk convenes for annual general meeting at Bella Center Copenhagen. That same day will also be the last for Jeppe Christiansen, CEO at Maj Invest, as a board member at the Danish drugmaker, reveals the meeting notice.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

Access all locked articles
Receive our daily newsletters
Access our app

Get full access for you and your coworkers

Start a free company trial today

Novo Nordisk and Lundbeck to remain in PhRMA despite news to the contrary
For subscribers
Lundbeck proposes Falck CEO and Novo Nordisk veteran as new board member
For subscribers
Novo Nordisk stock sets closing price record
For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Pharma & biotech

Eli Lilly's head of diabetes and obesity retires

Mike Mason announces that he will retire at the end of the year after 34 years with the company.

For subscribers

Pharma & biotech

DNB expects ALK's tablet sales to recover in 2024

For subscribers

Karin Absalonsen, now-former chairperson of Immunitrack and partner at Hannibal Innovation | Photo: Pr

Pharma & biotech

Eli Lilly makes acquisition in Denmark: Takes over company with 12 employees

For subscribers

Pharma & biotech

Pharmaceutical industry to grow 4% annually towards 2030

For subscribers

Pharma & biotech

Zealand Pharma CEO: "We've never been stronger"

For subscribers

Pharma & biotech

Investment bank: Novo Nordisk's patent victory is a small victory as price negotiations loom

For subscribers

FDA approves Novo Nordisk drug to treat rare condition
The marketing authorization applies to children and adolescents aged 9 years and older, as well as adults with ”relatively” preserved kidney functions.
For subscribers
Fujifilm expands management with former Leo executive
The contract manufacturer has hired a chief people officer with immediate effect.
For subscribers
Low share price may knock Galecto off the stock exchange
Nasdaq has requested that the biotech company raise its share price to above USD 1.
For subscribers
Snack maker keeps an eye on Novo Nordisk's obesity drug
”As with anything that could potentially impact our business, we’re looking at it,” says the former Kellogg’s CEO.
Olympus appoints new chief medical officer
The new medical director is brought in from Medtronic.
For subscribers
Novo Nordisk suffers Wegovy defeat to Viatris in patent court
It is the copy producer Viatris that has challenged three of the patents behind Novo Nordisk’s GLP-1 molecule Semaglutide.

Novo Nordisk chairman highlighted as candidate for CEO position at BP

British energy company BP is seeking a replacement for outgoing chief executive officer Bernard Looney. The company’s chairman, former Statoil boss Helge Lund, is named as a candidate.

For subscribers

Pharma & biotech